MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,666.45
+0.19%
NASDAQ 100
$30,501.56
+0.31%
DOW JONES
$50,927.00
+0.04%
NASDAQ Composite
$26,871.60
+0.04%
RUSSELL 2000
$2,790.20
+0.41%
CBOE VIX
$16.39
+0.31%
Sector Heatmap
Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%
ANVS — Annovis Bio, Inc.
NYSEAnnovis Bio, Inc.
$1.18
+0.01(+0.85%)
- O
- 1.19
- H
- 1.20
- L
- 1.14
- V
- 644.36K
⏱️ End-of-day dataAs of Oct 2, 2026
Chart
About ANVS
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
IndustryPHARMACEUTICAL PREPARATIONS
SectorNot available
IPO DateJan 29, 2020
Employees7
Stock ExchangeNYSE
Ticker SymbolANVS
Websitehttps://www.annovisbio.com
Key Financial Statistics
| Market Cap | $55.91M |
| P/E Ratio | N/A |
| Dividend Yield | N/A |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $1.04 - $132.00 |
| 52-Week Avg Volume | 477.3K |
| VWAP | $1.16 |
| Transactions | 2,852 |
| Total Recorded Bars | 1,679 days |